← Eichor
Study identifier: NCT06605417 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Understanding the Transition from Normal Melanocytes to Nevus to Melanoma

Condition: Congenital Melanocytic Nevi · Melanoma, Skin · Nevi and Melanomas  ·  Sponsor: Fundacion Clinic per a la Recerca Biomédica

PhaseN/A
Planned participants100
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in CAYA patients with L/GCMN. The secondary objectives are: * To longitudinally characterize the cell-free DNA (cfDNA) from CAYA patients. * To improve the early diagnosis and treatments for intermediate conditions such as L/GCMN through evidence-based interpretation of personal risk from endogenous or exogenous sources. * To test pre-clinical strategies to best model and improve patient response.

This description comes directly from the study's public registry record.

Talk to the study team

Susana Puig Sardà, MD, PhD  ·  +34932275400  ·  spuig@clinic.cat

Adrián López Canosa, PhD  ·  lopez64@recerca.clinic.cat

Always discuss trial participation with your own doctor first.

Locations (2)

French National Institute of Health and Medical ResearchMarseille, FranceRecruiting
Hospital Clínic de Barcelona (Dermatology service)Barcelona, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06605417